A new research report from the analysts at Cowen highlights the firm's top health care picks, many of which have some huge upside potential to the posted price targets.
What are investors, and patients, supposed to think when is launching a generic version of Diovan?
Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer drug binimetinib.
Chris Lange Wednesday's top analyst upgrades, downgrades and initiations include American Electric Power, BP, Halliburton, Cypress Semiconductor, J.C. Penney, Schlumberger and SanDisk.
A new research report from J.P. Morgan, makes the case that the time to buy some of the top stocks in Europe is right now.
For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
ThinkstockBinary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our 24/7 Wall…
These are the top Wall Street analyst upgrades, downgrades and initiations see on Monday, June 9, 2014. They include BioMarin, Family Dollar, Lululemon and SunTrust.
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy…
These are the top analyst upgrades, downgrades and initiations from Wall Street for Friday, May 2, 2014. They include Avanir, Avon, Broadcom, LinkedIn, Oracle and Wynn Resorts.
Mediwound offered 5 million shares in a Thursday IPO at the low end of the expected range. Akebia Therapeutics offered 5.9 million shares in its IPO at the high end of the…
Paul Ausick Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer immunotherapy portfolio.
ThinkstockSpeculation has run hot that Swiss drugmaker Novartis A.G. (NYSE: NVS) would announced further restructuring at its investor day in London. Instead, on Friday the company announced a $5 billion share buyback…
ThinkstockThe wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company ViroPharma (NASDAQ: VPHM) in…
